281 related articles for article (PubMed ID: 31480591)
21. Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers.
Cheng H; Borczuk A; Janakiram M; Ren X; Lin J; Assal A; Halmos B; Perez-Soler R; Zang X
Clin Cancer Res; 2018 Apr; 24(8):1954-1964. PubMed ID: 29374053
[No Abstract] [Full Text] [Related]
22. KRAS mutation-induced upregulation of PD-L1 mediates immune escape in human lung adenocarcinoma.
Chen N; Fang W; Lin Z; Peng P; Wang J; Zhan J; Hong S; Huang J; Liu L; Sheng J; Zhou T; Chen Y; Zhang H; Zhang L
Cancer Immunol Immunother; 2017 Sep; 66(9):1175-1187. PubMed ID: 28451792
[TBL] [Abstract][Full Text] [Related]
23. Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation.
Chen N; Fang W; Zhan J; Hong S; Tang Y; Kang S; Zhang Y; He X; Zhou T; Qin T; Huang Y; Yi X; Zhang L
J Thorac Oncol; 2015 Jun; 10(6):910-23. PubMed ID: 25658629
[TBL] [Abstract][Full Text] [Related]
24. 5-Fluorouracil upregulates cell surface B7-H1 (PD-L1) expression in gastrointestinal cancers.
Van Der Kraak L; Goel G; Ramanan K; Kaltenmeier C; Zhang L; Normolle DP; Freeman GJ; Tang D; Nason KS; Davison JM; Luketich JD; Dhupar R; Lotze MT
J Immunother Cancer; 2016; 4():65. PubMed ID: 27777774
[TBL] [Abstract][Full Text] [Related]
25. Role of regulatory T cells and checkpoint inhibition in hepatocellular carcinoma.
Langhans B; Nischalke HD; Krämer B; Dold L; Lutz P; Mohr R; Vogt A; Toma M; Eis-Hübinger AM; Nattermann J; Strassburg CP; Gonzalez-Carmona MA; Spengler U
Cancer Immunol Immunother; 2019 Dec; 68(12):2055-2066. PubMed ID: 31724091
[TBL] [Abstract][Full Text] [Related]
26. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
27. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma.
Görgün G; Samur MK; Cowens KB; Paula S; Bianchi G; Anderson JE; White RE; Singh A; Ohguchi H; Suzuki R; Kikuchi S; Harada T; Hideshima T; Tai YT; Laubach JP; Raje N; Magrangeas F; Minvielle S; Avet-Loiseau H; Munshi NC; Dorfman DM; Richardson PG; Anderson KC
Clin Cancer Res; 2015 Oct; 21(20):4607-18. PubMed ID: 25979485
[TBL] [Abstract][Full Text] [Related]
28. Fructose-1,6-bisphosphatase loss modulates STAT3-dependent expression of PD-L1 and cancer immunity.
Wang B; Zhou Y; Zhang J; Jin X; Wu H; Huang H
Theranostics; 2020; 10(3):1033-1045. PubMed ID: 31938049
[No Abstract] [Full Text] [Related]
29. Clinicopathological and prognostic significance of programmed cell death ligand-1 expression in lung adenocarcinoma and its relationship with p53 status.
Cha YJ; Kim HR; Lee CY; Cho BC; Shim HS
Lung Cancer; 2016 Jul; 97():73-80. PubMed ID: 27237031
[TBL] [Abstract][Full Text] [Related]
30. Trastuzumab upregulates programmed death ligand-1 expression through interaction with NK cells in gastric cancer.
Yamashita K; Iwatsuki M; Yasuda-Yoshihara N; Morinaga T; Nakao Y; Harada K; Eto K; Kurashige J; Hiyoshi Y; Ishimoto T; Nagai Y; Iwagami S; Baba Y; Miyamoto Y; Yoshida N; Ajani JA; Baba H
Br J Cancer; 2021 Feb; 124(3):595-603. PubMed ID: 33100329
[TBL] [Abstract][Full Text] [Related]
31. Luteolin and its derivative apigenin suppress the inducible PD-L1 expression to improve anti-tumor immunity in KRAS-mutant lung cancer.
Jiang ZB; Wang WJ; Xu C; Xie YJ; Wang XR; Zhang YZ; Huang JM; Huang M; Xie C; Liu P; Fan XX; Ma YP; Yan PY; Liu L; Yao XJ; Wu QB; Lai-Han Leung E
Cancer Lett; 2021 Sep; 515():36-48. PubMed ID: 34052328
[TBL] [Abstract][Full Text] [Related]
32. MET Inhibitors Promote Liver Tumor Evasion of the Immune Response by Stabilizing PDL1.
Li H; Li CW; Li X; Ding Q; Guo L; Liu S; Liu C; Lai CC; Hsu JM; Dong Q; Xia W; Hsu JL; Yamaguchi H; Du Y; Lai YJ; Sun X; Koller PB; Ye Q; Hung MC
Gastroenterology; 2019 May; 156(6):1849-1861.e13. PubMed ID: 30711629
[TBL] [Abstract][Full Text] [Related]
33. MACC1 regulates PDL1 expression and tumor immunity through the c-Met/AKT/mTOR pathway in gastric cancer cells.
Tong G; Cheng B; Li J; Wu X; Nong Q; He L; Li X; Li L; Wang S
Cancer Med; 2019 Nov; 8(16):7044-7054. PubMed ID: 31557409
[TBL] [Abstract][Full Text] [Related]
34. Macrophage migration inhibitory factor-CD74 interaction regulates the expression of programmed cell death ligand 1 in melanoma cells.
Imaoka M; Tanese K; Masugi Y; Hayashi M; Sakamoto M
Cancer Sci; 2019 Jul; 110(7):2273-2283. PubMed ID: 31069878
[TBL] [Abstract][Full Text] [Related]
35. The IFN-γ/PD-L1 axis between T cells and tumor microenvironment: hints for glioma anti-PD-1/PD-L1 therapy.
Qian J; Wang C; Wang B; Yang J; Wang Y; Luo F; Xu J; Zhao C; Liu R; Chu Y
J Neuroinflammation; 2018 Oct; 15(1):290. PubMed ID: 30333036
[TBL] [Abstract][Full Text] [Related]
36. Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune.
Jiang Z; Yang Y; Yang Y; Zhang Y; Yue Z; Pan Z; Ren X
Biomed Pharmacother; 2017 Dec; 96():378-383. PubMed ID: 29031195
[TBL] [Abstract][Full Text] [Related]
37. Green Tea Catechin Is an Alternative Immune Checkpoint Inhibitor that Inhibits PD-L1 Expression and Lung Tumor Growth.
Rawangkan A; Wongsirisin P; Namiki K; Iida K; Kobayashi Y; Shimizu Y; Fujiki H; Suganuma M
Molecules; 2018 Aug; 23(8):. PubMed ID: 30126206
[TBL] [Abstract][Full Text] [Related]
38. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells.
Botti G; Fratangelo F; Cerrone M; Liguori G; Cantile M; Anniciello AM; Scala S; D'Alterio C; Trimarco C; Ianaro A; Cirino G; Caracò C; Colombino M; Palmieri G; Pepe S; Ascierto PA; Sabbatino F; Scognamiglio G
J Transl Med; 2017 Feb; 15(1):46. PubMed ID: 28231855
[TBL] [Abstract][Full Text] [Related]
39. Inhibition of COX-2 and EGFR by Melafolone Improves Anti-PD-1 Therapy through Vascular Normalization and PD-L1 Downregulation in Lung Cancer.
Tang H; Liu Y; Wang C; Zheng H; Chen Y; Liu W; Chen X; Zhang J; Chen H; Yang Y; Yang J
J Pharmacol Exp Ther; 2019 Mar; 368(3):401-413. PubMed ID: 30591531
[TBL] [Abstract][Full Text] [Related]
40. Regulation of PD-L1: a novel role of pro-survival signalling in cancer.
Chen J; Jiang CC; Jin L; Zhang XD
Ann Oncol; 2016 Mar; 27(3):409-16. PubMed ID: 26681673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
